HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wockhardt’s Illinois Drug Firm Closed In FDA Settlement After GMP Problems Found Since 2011

Executive Summary

Permanent injunction states Morton Grove Pharmaceuticals intends to sell its facility. Complaint comes more than 10 years after first of five inspections found GMP problems.

You may also be interested in...

After Consent Decree, Wockhardt May Sell US Site Amid Wider Revamp

Wockhardt’s US arm Morton Grove Pharmaceuticals, which is bound by a consent decree of permanent injunction, discontinues production to undertake an “orderly closure” and potential sale of its Illinois site. Indian parent firm taps contract manufacturers to service US market.

Deals Shaping the Medical Industry (12/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Morton Grove Pharmaceuticals sold to ex-Fujisawa USA President Tambi.

MORTON GROVE PHARMACEUTICALS SOLD TO FORMER FUJISAWA USA PRESIDENT TAMBI and Chicago-based William Blair Capital Partners. In a transaction announced Dec. 12, Brian Tambi acquired Morton Grove Pharmaceuticals, Inc. from JVL, Inc., a holding company formed by Jack Van Hulst and William Lyons. Tambi will serve as MGP's chairman, president and CEO. He previously was an exec at Lyphomed when it was acquired by Fujisawa. He was appointed Fujisawa USA president in 1990 and joined Ivax in 1992 as president of its North American pharmaceutical business.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts